Cyclacel Begins a Phase IIb Randomized Trial of Seliciclib for Previously Treated Non-Small Cell Lung Cancer
Cyclacel Pharmaceuticals, Inc. announced today that the company is beginning a Phase IIb, multi-center, randomized, double-blinded trial to evaluate the efficacy and safety of the investigational drug seliciclib, an orally available molecule that targets cyclin dependent kinases, as a third line treatment in patients with non-small cell lung cancer.
This entry was posted on Monday, July 3rd, 2006 at 9:28 am and is filed under Research, Non-Small-Cell, Treatment. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.